Target intelligence / Profile preview

Protein S-palmitoylation (null)

Target
null
Molecular classification
Other (specifically, Post-translational modification)
01

Overview

Protein S-palmitoylation is a reversible lipid modification in which a palmitoyl group is attached to the sulfur atom of cysteine residues in target proteins via a thioester bond. This modification is catalyzed by DHHC-family palmitoyltransferases and reversed by acyl-protein thioesterases. S-palmitoylation regulates diverse protein functions, including membrane association, stability, localization, trafficking, and protein-protein interactions. It is essential in processes such as signal transduction, immune response, and synaptic function. Dysregulation of protein S-palmitoylation is implicated in numerous pathological conditions, notably cancer, neurodegenerative, cardiovascular, and immune-mediated diseases. Pharmacological modulation of S-palmitoylation is an emerging area in therapeutic development, though non-specificity and safety remain major challenges

Other names
PalmitoylationS-acylationS-palmitoylation
02

Mechanism of action

Inhibition of S-palmitoylation via DHHC-palmitoyltransferase blockade (e.g., 2-BP inhibits the enzyme family responsible for palmitoylation)\nModulation of immune signaling, tumor signaling pathways, and protein localization through altered palmitoylation status

03

Biological functions

Signal transductionProtein-membrane associationTraffickingProtein stabilityCell adhesionImmune responseTranscriptional regulationCellular differentiationProtein-protein interaction
04

Disease associations

CancerNeurodegenerative disease (e.g., Alzheimer’s, Parkinson’s)Cardiovascular diseaseImmunologic diseaseInfectionInflammation
05

Safety considerations

Lack of specificity for inhibitors (such as 2-Bromopalmitate inhibits multiple lipid-processing enzymes)Potential for widespread cellular effects, given the large number of palmitoylated proteins and the role in fundamental processes
06

Interacting drugs

2-Bromopalmitate (2-BP; a nonspecific inhibitor of palmitoylation)

1 more in the full profile.

07

Biomarkers

None specific to S-palmitoylation as a modification; altered palmitoylation patterns of specific proteins may serve as biomarkers in cancer and other diseases but are not universally established or clinically validated

Beyond the preview

Go deeper on Protein S-palmitoylation (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein S-palmitoylation (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call